Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 3/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14597712 | 1.00 | TACR1 (0.41) | TACR1MGLLKCNQ2HSD17B2LIPG | |
| SCHEMBL14628402 | 0.92 | HSD17B2 (0.41) | TACR1MGLLKCNQ2HSD17B2NAAA | |
| SCHEMBL1176585 | 0.89 | TACR1 (0.42) | TACR1MGLLKCNQ2HSD17B2NAAA | |
| SCHEMBL1176581 | 0.89 | TACR1 (0.42) | TACR1MGLLKCNQ2HSD17B2NAAA | |
| SCHEMBL5820901 | 0.89 | TACR1 (0.42) | TACR1MGLLKCNQ2HSD17B2NAAA | |
| SCHEMBL1176583 | 0.89 | TACR1 (0.42) | TACR1MGLLKCNQ2HSD17B2NAAA | |
| SCHEMBL2706185 | 0.89 | TACR1 (0.42) | TACR1MGLLKCNQ2HSD17B2NAAA | |
| SCHEMBL6181877 | 0.85 | TACR1 (0.44) | TACR1MGLLKCNQ2NAAAKIF11 | |
| SCHEMBL6181879 | 0.85 | TACR1 (0.44) | TACR1MGLLKCNQ2NAAAKIF11 | |
| SCHEMBL6181885 | 0.85 | TACR1 (0.44) | TACR1MGLLKCNQ2NAAAKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1670765-A2 | CETP INHIBITORS AND METABOLITES THEREOF | Pfizer Products Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005033082-A2 | CETP INHIBITORS AND METABOLITES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | CETP, LCAT, MTTP | TACR1 1028/4885MGLL 425/4885KCNQ2 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.